AssetID: 55291980
Headline: Semaglutide Fails To Slow Alzheimer's Progression In Major Novo Nordisk Trials
Caption: Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic and Wegovy has failed to slow the progression of Alzheimer’s disease in two highly anticipated Phase 3 trials
Keywords: Health & WEllbeing,semaglutide,fails,slow,alzheimer's,progression,major trial,novo nordisk,dementia,weight-loss drug,blocker,ozempic,Wegovy,phase 3 trials
PersonInImage: